SORIN’S NEW BOARD OF DIRECTORS’ ASSIGNS APPOINTMENTS AND POWERS TO DIRECTORS
Milan, 4 May 2012– At a meeting held today, the Board of Directors of Sorin S.p.A., appointed by the Stockholders’ meeting held on April 30th, 2012, resolved, inter alia, on Company’s appointments and powers to the Directors.
Rosario Bifulco has been appointed Chairman of the Board, whilst Giovanni Pavese has been appointed Deputy Chairman.
André-Michel Ballester has been confirmed Chief Executive Officer.
An Executive Committee has been also established composed of the Chairman, the Chief Executive Officer and the Directors Maurizia Squinzi and Andrea Bovone.
The Board of Directors also established the Compensation Policies Committee, the Control & Risk Committee and the Committee for Transactions with Related Parties.
The Board of Directors has evaluated, based on information provided by the interested parties or in any event available to the company, the possession by members of the Board of Directors of the independence requirements envisaged in Article 148, subsection 3 of the Consolidated Law and recommended by the Corporate Governance Code promoted by Borsa Italiana S.p.A..
* * *
About Sorin Group
Sorin Group (www.sorin.com) is a global company and a leader in the treatment of cardiovascular diseases. The company develops, manufactures and markets medical technologies and innovative therapies for cardiac surgery and for the treatment of cardiac rhythm disorders. With 3,750 employees worldwide, the Company focuses on three major therapeutic areas: cardiopulmonary bypass (extra-corporeal circulation and autotransfusion systems), cardiac rhythm management, and repair and substitution of heart valves. Each year, over one million patients are treated with the devices of Sorin Group in more than 80 countries.
For further information, visit: www.sorin.com, or contact:
Director, Corporate Communications
Tel: +33 (0)1 46 01 33 78
Mobile: +33 (0)6 76 12 67 73
Director, Investor Relations
Tel: +39 02 69969716